GlassScriptPhysician profile
James L Strong
NPI 1619970290
$38,660.82
in general payments reported to CMS, 2019-2025
78 companies · $6,512 in 2025
The $6,512 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,833 · 2020: $4,338 · 2021: $5,037 · 2022: $5,660 · 2023: $5,737 · 2024: $7,545 · 2025: $6,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Education: $22.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,771.43 |
| Education | $22.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,649.55 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $2,560.03 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Novartis Pharmaceuticals Corporation | $2,187.94 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $1,445.48 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $1,362.50 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $1,279.09 | 2019-2025 | |
| Csl Behring | $1,222.04 | 2020-2025 | Hizentra |
| Allergan, INC. | $1,206.27 | 2019-2022 | |
| Lilly USA, LLC | $1,198.89 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $1,192.72 | 2020-2025 | Ingrezza, Ongentys |
| Eisai INC. | $1,145.89 | 2019-2025 | |
| Genentech USA, INC. | $1,085.68 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $1,017.60 | 2019-2025 | Uplizna, Aimovig |
| Acorda Therapeutics, INC | $1,012.49 | 2019-2024 | Inbrija, Ampyra |
| Sk Life Science, INC. | $1,011.31 | 2020-2025 | Xcopri |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Strong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.